Qu Jian, Qi Ting-Ting, Qu Qiang, Long Wen-Ming, Chen Ying, Luo Yue, Wang Ying
Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, People's Republic of China.
Institute of Clinical Pharmacy, Central South University, Changsha, 410011, People's Republic of China.
Infect Drug Resist. 2022 Mar 22;15:1205-1218. doi: 10.2147/IDR.S357746. eCollection 2022.
The increasing prevalence of carbapenem-resistant Gram-negative bacteria (CR-GNB) represents a global healthcare crisis. This study explored the efficacy and safety of Polymyxin B (PMB)-based regimens and factors influencing their effectiveness.
Patients with CR-GNB infections treated with PMB for more than three days were enrolled in this retrospective study from 1st June 2018 to 30th April 2020. Data were collected on patient characteristics, bacterial culture, and drug-sensitivity test results; anti-infection treatment regimens, particularly details of PMB use; and adverse drug reactions. Clinical and microbiological efficacy, mortality, and safety of PMB-based regimens in CR-GNB infected patients were evaluated. Univariate analysis and multivariate logistic regression analyses were used to assess factors influencing efficacy and mortality.
A total of 373 CR-GNB strains were cultured from 268 patients. About 41.04% of patients used PMB loading dose of 1.01 (0.84-1.69) mg/kg. Maintenance dose was 0.85 (0.82-1.00) mg/kg q12h. The clinical efficacy rate was 36.57% (98/268), the total bacterial clearance rate of PMB was 39.42%, and the all-cause mortality rate was 33.96%. The adverse drug reaction rate was 19.58%, among which the incidence of renal toxicity was highest (8.21%). Multivariate logistic regression analysis showed that clinical efficacy, bacterial clearance rate, and all-cause mortality were associated with patient-related facts, including mechanical ventilation use, underlying diseases (such as respiratory disease), the type and site of CR-GNB infection, and PMB administration timing and loading dose.
PMB is a relatively safe and effective antibiotic drug for treatment of critically ill patients with CR-GNB infection; however, PMB use should be subject to guidelines recommendations for early administration, loading administration, and adequate administration, which could help to improve the clinical efficacy, microbiological efficacy, and mortality.
耐碳青霉烯类革兰氏阴性菌(CR-GNB)的患病率不断上升,这是一场全球医疗危机。本研究探讨了基于多粘菌素B(PMB)的治疗方案的疗效和安全性以及影响其有效性的因素。
本回顾性研究纳入了2018年6月1日至2020年4月30日期间接受PMB治疗超过三天的CR-GNB感染患者。收集了患者特征、细菌培养和药敏试验结果;抗感染治疗方案,特别是PMB使用细节;以及药物不良反应的数据。评估了基于PMB的治疗方案在CR-GNB感染患者中的临床和微生物学疗效、死亡率及安全性。采用单因素分析和多因素逻辑回归分析评估影响疗效和死亡率的因素。
共从268例患者中培养出373株CR-GNB菌株。约41.04%的患者使用的PMB负荷剂量为1.01(0.84-1.69)mg/kg。维持剂量为0.85(0.82-1.00)mg/kg,每12小时一次。临床有效率为36.57%(98/268),PMB的总细菌清除率为39.42%,全因死亡率为33.96%。药物不良反应发生率为19.58%,其中肾毒性发生率最高(8.21%)。多因素逻辑回归分析表明,临床疗效、细菌清除率和全因死亡率与患者相关因素有关,包括机械通气的使用、基础疾病(如呼吸系统疾病)、CR-GNB感染的类型和部位以及PMB给药时机和负荷剂量。
PMB是治疗CR-GNB感染重症患者的一种相对安全有效的抗生素药物;然而,PMB的使用应遵循早期给药、负荷给药和充分给药的指南建议,这有助于提高临床疗效、微生物学疗效和降低死亡率。